证券代码：688247 证券简称：宣泰医药 公告编号：2026-001

Group 1 - The company has received approval from the National Medical Products Administration for the marketing of injectable isavuconazole, which is indicated for the treatment of invasive aspergillosis and mucormycosis in adult patients [1][4] - The original product was developed by Pfizer and was approved for marketing in China in June 2022, subsequently included in the Class B medical insurance catalog, leading to rapid market growth [1][2] - According to sales data from MoSheng Pharmaceuticals, the projected sales for the product are RMB 204 million for the year 2024 and RMB 172 million for the first half of 2025 [1] Group 2 - The approval of injectable isavuconazole is expected to enrich the company's product line and enhance its competitiveness, positively impacting future operating performance [2] - However, the specific sales performance may be influenced by various factors such as market conditions and channel expansion, introducing a degree of uncertainty [2]